Sanofi (SNY)
44.32
-0.14
(-0.33%)
USD |
NASDAQ |
Sep 03, 16:00
44.32
0.00 (0.00%)
After-Hours: 16:26
Sanofi Research and Development Expense (Annual) : 8.845B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 8.845B |
| December 31, 2024 | 7.997B |
| December 31, 2023 | 7.032B |
| December 31, 2022 | 7.047B |
| December 31, 2021 | 6.724B |
| December 31, 2020 | 6.302B |
| December 31, 2019 | 6.732B |
| December 31, 2018 | 6.949B |
| December 31, 2017 | 6.147B |
| December 31, 2016 | 5.704B |
| December 31, 2015 | 5.621B |
| December 31, 2014 | 6.175B |
| December 31, 2013 | 6.315B |
| December 31, 2012 | 6.284B |
| December 31, 2011 | 6.669B |
| Date | Value |
|---|---|
| December 31, 2010 | 6.002B |
| December 31, 2009 | 6.353B |
| December 31, 2008 | 6.674B |
| December 31, 2007 | 6.188B |
| December 31, 2006 | 5.528B |
| December 31, 2005 | 4.970B |
| December 31, 2004 | 2.981B |
| December 31, 2003 | 1.487B |
| December 31, 2002 | 1.149B |
| December 31, 2001 | 922.32M |
| December 31, 2000 | 870.28M |
| December 31, 1999 | 969.42M |
| December 31, 1998 | 148.63M |
| December 31, 1997 | 908.04M |
| December 31, 1996 | 957.40M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| AstraZeneca PLC | 13.84B |
| GSK Plc | 8.171B |
| Johnson & Johnson | 14.83B |
| Eli Lilly & Co. | 13.34B |
| Merck & Co., Inc. | 12.51B |